Abstracts tagged "giant cell arteritis"

Abstract Number: 2390 • ACR Convergence 2023
Characterization of Senescent Cells in Temporal Arteries of Patients with Giant Cell Arteritis Reveal an Inflammatory Phenotype and Strong Dependence from IL-6
Dimitrios Veroutis¹, Ourania D Argryropouou¹, Andreas Goules², Konstantinos Kambas³, Dimitris Anastasios Palamidas¹, Konstantinos Evangelou¹, Sophia Havaki¹, Aikaterini Polyzou¹, Evangelia Xingi³, Elli Karatza⁴, Kyriaki Boki⁵, alberto cavazza⁶, Christos Kittas¹, Dimitris Thanos⁷, caterina Ricordi⁶, chiara marvisi⁶, Francesco Muratore⁸, Elena Galli⁶, Stefania Croci⁶, Carlo Salvarani⁹, Vassilis G Gorgoulis¹ and Athanasios Tzioufas², ¹National and Kapodistrian University of Athens, Athens, Greece, ²Dept. of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ³Hellenic Pasteur Institute, Athens, Greece, ⁴Laikon General Hospital, Athens, Greece, ⁵Sismanoglion Hospital, Athens, Greece, ⁶Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁷Biomedical Research Foundation of the Academy of Athens, Athens, Greece, ⁸IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁹Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Age is the strongest risk factor of giant cell arteritis (GCA), implying a possible pathogenetic role of cellular senescence. So far, no studies have…
Abstract Number: 2407 • ACR Convergence 2023
Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis
Shozo Ohtsuki¹, Chenyao Wang², Ryu Watanabe³, Hui Zhang³, Mitsuhiro Akiyama³, Kenneth Warrington⁴, Gerald J. Berry³, Jorg Goronzy⁴ and Cornelia M. Weyand⁵, ¹Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Stanford University School of Medicine, Stanford, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Giant cell arteritis (GCA) is a medium and large vessel vasculitis with pathognomonic granulomatous infiltrates in the vessel wall. During the early stages of…
Abstract Number: 2557 • ACR Convergence 2023
Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades
Mahmut Kaymakci¹, Nicholas Boire¹, Melanie Bois¹, Mohanad Elfishawi¹, Hannah Langenfeld², Andrew Hanson², Cynthia Crowson¹, Matthew Koster¹, Cornelia M. Weyand³ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Patients with giant cell arteritis (GCA) are at increased risk of thoracic aortic aneurysm and dissection. This late complication of the disease is presumed…
Abstract Number: 0696 • ACR Convergence 2023
Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study
Francois Maillet¹, Yann Nguyen², Olivier Espitia³, Laurent Perard⁴, Carlo Salvarani⁵, Etienne Rivière⁶, Cécile-Audrey Durel⁷, Philippe GUILPAIN⁸, Luc Mouthon⁹, Anna Kernder¹⁰, Javier Loricera¹¹, Pascal Cohen¹², Isabelle Melki¹³, Claire De Moreuil¹⁴, Nicolas Limal¹⁵, Arsène Mekinian¹⁶, Nathalie Costedoat-Chalumeau¹⁷, Nathalie Morel¹², Jonathan Boutemy¹⁸, Loic Raffray¹⁹, Jean-Sébastien Allain²⁰, Valerie Devauchelle²¹, Isabelle Kone-Paut²², Marc Fabre²³, Marie Durel²⁴, Antoine Dossier²⁵, Sébastien Abad²⁶, Marcella Visentini²⁷, Adrien Bigot²⁸, Halil Yildiz²⁹, Olivier Fain³⁰, Maxime Samson³¹, Guillaume Gondran³², Vered Abitbol¹ and Benjamin Terrier³³, ¹Cochin Hospital, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³CHU de Nantes, Nantes, France, ⁴CH Saint Hoseph Saint Luc, Lyon, France, ⁵Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ⁶CHU Bordeaux, Bordeaux, France, ⁷CHU Lyon, Lyon, France, ⁸University of Montpellier, Montpellier, France, ⁹Hopital Cochin - Paris University, Paris, France, ¹⁰HHU Düsseldorf, Düsseldorf, Germany, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²CHU Cochin, Paris, France, ¹³Hopital Robert Debré, Sérurier, France, ¹⁴CHU de Brest, Brest, France, ¹⁵AP-HP, Créteil, France, ¹⁶Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ¹⁷Inserm DR Paris 5, Paris, France, ¹⁸CHU de Caen, Caen, France, ¹⁹CHU la Réunion, La Réunion, France, ²⁰CHU Rennes, Rennes, France, ²¹UBO, Brest, France, ²²Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France, ²³CH Bourgoin-Jallieu, Bourgoin-Jallieu, France, ²⁴CH Metz, Metz, France, ²⁵AP-HP, Paris, France, ²⁶Avicenne Hospital, Bobigny, France, ²⁷Rome Hospital, Rome, France, ²⁸Tours Hospital, Tours, France, ²⁹Saint Luc Hospital, Bruxelles, Belgium, ³⁰Hopital SAINT ANTOINE APHP, Paris, France, ³¹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³²Limoges Hospital, Limoges, France, ³³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The association of large vessel vasculitis (LVV), whether Takayasu arteritis (TA) or giant cell arteritis (GCA), with inflammatory bowel disease (IBD) is a rare…
Abstract Number: 1645 • ACR Convergence 2023
Aortic Dilatation and PET/CT Vascular Activity at Diagnosis and 5 Years in an Inception Giant Cell Arteritis (GCA) Cohort
Anthony Sammel¹, Ivan Ho Shon², Daniel Moses¹, Fredericks Stacey¹, Gita Mathur¹, Claudia Hillenbrand³, Edward Hsiao⁴, Schembri Geoffrey⁴, Rodger Laurent⁴ and Eva Wegner², ¹Prince of Wales Hospital, Randwick, Australia, ²The Prince of Wales Hospital, Sydney, Australia, ³University of NSW, Randwick, Australia, ⁴Royal North Shore Hospital, St. Leonards, Australia
Background/Purpose: Aortic dilatation is typically a late complication of giant cell arteritis (GCA) but there are no tools to risk stratify patients at the time…
Abstract Number: 2391 • ACR Convergence 2023
Epidemiology and Predictors of Relapse in Giant Cell Arteritis: Results of the ARTESER Register
Javier Narvaez¹, Jesús Sanchez-Costa², Iñigo Hernández-Rodríguez³, Rafael Benito Melero-Gonzalez⁴, Eugenio De Miguel⁵, Irene Monjo⁶, Maite silva díaz⁷, LUCIA SILVA FERNANDEZ⁸, Joaquin Maria Belzunegui Otano⁹, Jesus Alejandro Valero-Jaimes¹⁰, Clara Moriano Morales¹¹, Ismael González¹², Julio Sanchez Martin¹³, Tomas Almorza Hidalgo¹⁴, Judit Lluch¹⁵, Eva Galindez-Agirregoikoa¹⁶, Itziar Calvo-Zorrilla¹⁶, Vicente Aldasoro¹⁷, Javier Mendizabal¹⁸, LYDIA ABASOLO¹⁹, PIA LOIS²⁰, Javier Loricera¹³, Noemi Garrido-Puñal²¹, ALBERTO MARIANO RUIZ ROMAN²², Santos Castañeda²³, Cristina Valero²³, Patricia Moya Albarado²⁴, Hector Corominas²⁵, Maria J. García-Villanueva²⁶, Carmen Larena²⁷, Paula V. Estrada-Alarcón²⁸, Vanessa Navarro²⁹, Carles Galisteo³⁰, Anne Riveros-Frutos³¹, Francisco Miguel Ortiz Sanjuan³², Selene Labrada-Arrabal³³, María Alcalde³⁴, Clara Molina Almela³⁵, Carlos Garcia Porrua³⁶, Maria García-González³⁷, Margarida Rocha³⁸, Antonio Juan Mas³⁹, Miguel A Gonzalez-Gay⁴⁰ and Ricardo Blanco⁴¹, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain, ³Hospital do Meixoeiro. Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁴CHU Vigo, O Carballino, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶University Hospital La Paz, Madrid, Spain, ⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, ⁸Complejo Hospitalario Universitario de la Coruña, Pontevedra, Spain, ⁹University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁰Hospital Bidasoa, Irún, Spain, ¹¹Rheumatology, Hospital Universitario de León, León, Spain, ¹²Hospital Universitario de León, León, Spain, ¹³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁵Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Basurto University Hospital, Bilbao, Spain, ¹⁷Hospital Universitario de Navarra, Pamplona, Spain, ¹⁸Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁹Hospital Clínico San Carlos, Madrid, Spain, ²⁰Hospital Clinico San Carlos, Madrid, Spain, ²¹Hospital Universitario Virgen del Rocío, Sevilla, Spain, ²²Department of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ²³Hospital Universitario de la Princesa, Madrid, Spain, ²⁴Hospital Universitario de Sant Pau, Barcelona, Spain, ²⁵Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, ²⁶Hospital Ramón y Cajal, Madrid, Spain, ²⁷Hospital Universitario Ramon y Cajal, Madrid, Spain, ²⁸Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁹Hospital de Sant Joan Despí – Moises Broggi, Barcelona, Spain, ³⁰Hospital Universitario Parc Taulí, Sabadell, Spain, ³¹Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ³²Hospital Universitario y Politecnico La Fe, Valencia, Spain, ³³Hospital del Mar, Barcelona, Spain, ³⁴Hospital Severo Ochoa, Madrid, Spain, ³⁵Hospital General de Valencia, Valencia, Spain, ³⁶Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³⁸Osakidetza, Bilbo, Spain, ³⁹Hospital Universitario Son Llàtzer, Mallorca, Spain, ⁴⁰IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁴¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The relapse rate of treated patients with giant cell arteritis (GCA) varied widely in observational series and randomized controlled trials. This study aimed to…
Abstract Number: 2408 • ACR Convergence 2023
The Use of the Southend GCA Probability Score (GCAPS) in Assessing the Risk of Giant Cell Arteritis in Australian Ophthalmological and General Medical Hospital Cohorts
Eloise Norman¹, Clare Fraser², Mitchell Lawlor³ and Anthony Sammel⁴, ¹Prince of Wales Hospital, Randwick, Australia, ²Save Sight Institute, The University of Sydney, Sydney, Australia, ³Sydney and Sydney Eye Hospital, Sydney, Australia, ⁴The Prince of Wales Hospital, Sydney, Australia
Background/Purpose: The rate of positive temporal artery biopsies (TAB) in patients with suspected giant cell arteritis (GCA) varies widely, indicating the need for better pre-test…
Abstract Number: 2558 • ACR Convergence 2023
Aortic Aneurysms in a Multicenter Cohort of 196 Patients with Aortitis Related to Giant Cell Arteritis Treated with Tocilizumab
Fernando López¹, Javier Loricera², Adrián Martín-Gutiérrez³, Carmen Secada³, Santos Castañeda⁴, Clara Moriano Morales⁵, Javier Narvaez⁶, Vicente Aldasoro⁷, Olga Maiz⁸, Rafael Benito Melero-Gonzalez⁹, PALOMA VELA¹⁰, Susana Romero Yuste¹¹, Eugenio De Miguel¹², Eva Galindez-Agirregoikoa¹³, Jesús Carlos Fernández López¹⁴, Ivan Ferraz Amaro¹⁵, Julio Sánchez-Martín³, Jose L. Callejas¹⁶, Patricia Moya Albarado¹⁷ and Ricardo Blanco¹⁸, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de León, León, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital Universitario de Navarra, Pamplona, Spain, ⁸Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ⁹CHU Vigo, O Carballino, Spain, ¹⁰Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Basurto University Hospital, Bilbao, Spain, ¹⁴Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁶Unit of Systemic Autoimmune Diseases, Hospital San Cecilio, Granada, Spain, ¹⁷Hospital Universitario de Sant Pau, Barcelona, Spain, ¹⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Aortic aneurysms is a serious complication that can occur in patients with giant cell arteritis (GCA) (1-2). Tocilizumab (TCZ) is approved for GCA. Nevertheless,…
Abstract Number: 0697 • ACR Convergence 2023
Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis
Adam Mayer¹, Weiming Hu², Kyle Bittinger², Rui Liang³, Naomi Amudala³, Shubhasree Banerjee³, Peter Merkel³ and Rennie Rhee³, ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: The gut microbiome has a critical role in immune homeostasis and there is growing interest in understanding the relationship between the microbiome and autoimmunity.…
Abstract Number: 1646 • ACR Convergence 2023
The Real-World Experience of Combined Cranial and Large Vessel FDG-PET/CT in the Investigation of Giant Cell Arteritis
Keren Port¹, Ivan Ho Shon¹, Sally Ayesa¹, Rachel Langford¹, Olivia Bennett¹, Andrew Csillag¹, Stacey Fredericks¹, Luz Palacios-Derflingher², Eva Wegner¹ and Anthony Sammel¹, ¹The Prince of Wales Hospital, Sydney, Australia, ²University of New South Wales, Sydney, Australia
Background/Purpose: GCA is a systemic medium-large vessel vasculitis (M-LVV) involving the cranial arteries, aorta and its major branches. Recent studies have shown that PET/CT including…
Abstract Number: 2392 • ACR Convergence 2023
Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis
andre ramon¹, helene Greigert², corentin Richard³, claudie cladière⁴, coraline genet⁵, marion ciudad⁶, georges tarris⁷, laurent martin⁸, louis arnould⁹, catherine creuzot-garcher¹⁰, paul ornetti¹¹, Sylvain Audia¹², romain boidot³, jean-Francis Maillefert¹¹, Bernard Bonnotte² and Maxime Samson², ¹Department of Rheumatology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Département de Biologie et de Pathologie des Tumeurs, ICMUB UMR CNRS 6302, Centre Georges François Leclerc, Dijon, France, ⁴INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, ⁵INSERM 1098 RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁶INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁷Department of Pathology, Dijon-Bourgogne university Hospital, Dijon, France, ⁸Department of Pathology, Dijon University Hospital, Dijon, France, ⁹Department of Ophtalmology, Dijon-Bourgogne university Hospital, Dijon, France, ¹⁰Department of Ophthalmology, Dijon University Hospital, Dijon, France, ¹¹Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France, ¹²Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France
Background/Purpose: Polymyalgia rheumatica (PMR) is associated with giant cell arteritis (GCA) in 16 to 21% of cases. This raises the question of a pathophysiological continuum…
Abstract Number: 2409 • ACR Convergence 2023
Concordance of Relapse Symptoms with Initial Baseline Presentation Features Among Patients with Giant Cell Arteritis
Max Guarda¹, Andrew Hanson², Hannah Langenfeld², Cynthia Crowson¹, Jigisha Rakholiya³, Cristian Labarca⁴, Cornelia M. Weyand⁵, Kenneth Warrington¹ and Matthew Koster¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Pueblo, CO, ⁴Clinica Alemana de Santiago, Santiago, Chile, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Relapse is common in giant cell arteritis (GCA) with 40-75% of patients having at least one flare during course of disease. A clinically relevant…
Abstract Number: 2560 • ACR Convergence 2023
Risk of Gastrointestinal Perforation Among Patients with Giant Cell Arteritis Who Received Tocilizumab
Desh Nepal¹, Sebastian Sattui², Zachary Wallace³ and Mike Putman⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²University of Pittsburgh, Pittsburgh, PA, ³Massachusetts General Hospital, Newton, MA, ⁴Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Exposure to the interleukin-6 inhibitor tocilizumab has been associated with an increased risk of gastrointestinal (GI) perforation in patients with rheumatoid arthritis. No studies…
Abstract Number: 0699 • ACR Convergence 2023
T Cell Subset Analysis in Patients with Large-Vessel Vasculitis
Rebecca Kuan¹, Christopher Redmond¹, McKella Sylvester², Mary Maclean¹, Francoise Meylan¹, Marcela Ferrada¹, Kaitlin Quinn¹ and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Colgate University, Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by granulomatous inflammation of the aorta and its major branches. The two major forms are giant cell arteritis (GCA)…
Abstract Number: 1647 • ACR Convergence 2023
Association Between Vascular FDG Uptake at Diagnosis and Evolution in Aortic Dimensions in Giant Cell Arteritis: A Prospective Study
Lien Moreel¹, Walter Coudyzer², Lennert Boeckxstaens³, Albrecht Betrains¹, Geert Molenberghs⁴, Steven Vanderschueren¹, Eveline Claus², Koen Van Laere⁵ and Daniel Blockmans¹, ¹Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ²Department of Radiology, University Hospitals Leuven, Leuven, Belgium, ³Department of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium, ⁴Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), University of Leuven and Hasselt University, Leuven, Belgium, ⁵Department of Nuclear Medicine, University Hospitals Leuven,Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgium
Background/Purpose: Patients with giant cell arteritis (GCA) have an increased risk of developing thoracic aortic aneurysms. Retrospective studies have shown that 18F-fluorodeoxyglucose (FDG) uptake in…

« Previous Page
1
…
4
5
6
7
8
…
32
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.